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Background: Three Komondor dogs in a small family and 3 sporadic cases exhibited a constellation of signs that
included juvenile-onset of failure-to-thrive, inappetence, vomiting and/or diarrhea, and weakness. In each we
documented dyshematopoiesis, increased anion gap, methylmalonic acidemia/-uria, and serum cobalamin
deficiency. Urine protein electrophoresis demonstrated excretion of cubam ligands. All clinical signs and metabolic
abnormalities, except proteinuria, were reversed by regular parenteral cobalamin administration. The pattern of
occurrence and findings in the disorder suggested an autosomal recessive inheritance of cobalamin malabsorption
with proteinuria, a condition in humans called Imerslund-Gräsbeck syndrome. The purpose of this study was to
determine the molecular cause of this disorder in Komondors.
Results: Whole genome sequencing of two affected Komondor dogs of unknown relatedness and one parent and
a clinically-normal littermate of an affected dog revealed a pathogenic single-base change in the CUBN intron 55
splice donor consensus sequence (NM_001003148.1: c.8746 + 1G > A) that was homozygous in affected dogs and
heterozygous in the unaffected parents. Alleles of the variant co-segregated with alleles of the disease locus in the
entire family and all more distantly-related sporadic cases. A population study using a simple allele-specific DNA
test indicated mutant allele frequencies of 8.3 and 4.5% among North American and Hungarian Komondors,
respectively.
Conclusions: DNA testing can be used diagnostically in Komondors when clinical signs are suggestive of
cobalamin deficiency or to inform Komondor breeders prospectively and prevent occurrence of future affected
dogs. This represents the third cubilin variant causing inherited selective cobalamin malabsorption in a large animal
ortholog of human Imerslund-Gräsbeck syndrome.
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Failure to thriveBackground
Cobalamin (vitamin B12) is an essential micronutrient for
mammals that, when metabolized to the forms 5′-adeno-
syl cobalamin and methyl-cobalamin, serves as a cofactor
for two enzymes, methylmalonyl-CoA mutase and me-
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zymatic activities. Unprocessed substrates are observed
as methylmalonic acidemia/-uria and homocysteinemia,
while secondary metabolites disrupt ammonia elimin-
ation, glucose homeostasis, and nucleotide synthesis.
Thus, clinical signs of severe cobalamin deficiency and its
metabolic effects are far reaching and include dyshemato-
poiesis, gastrointestinal (GI) disturbances, post-natal
developmental delay, and life-threatening metabolic
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isms, and monogastric species obtain this vitamin from
animal-derived foods via a complex receptor-mediated
mechanism of the GI tract initially delineated in William
Castle’s investigations of pernicious anemia [3]. Successful
cobalamin absorption is a sequence of protein-binding
events that each depend on the longitudinal secretory and
absorptive organization of the GI tract [4]. The daily diet-
ary cobalamin requirement in dogs is 2–3 μg, and there is
a large flux of enterohepatic recirculation of the vitamin.
Cobalamin deficiency is most often caused by GI malab-
sorption, rather than dietary deficiency, occurring either
as generalized GI malabsorption or as a selective process
in which cobalamin is the only dietary component that is
lost. Hereditary selective cobalamin malabsorption is
caused mainly by defects that interrupt secretion or func-
tion of intrinsic factor (IF), a protein product of gastric
parietal cells in humans and pancreatic duct cells in dogs,
or of cubam, the highly specific, IF-cobalamin receptor on
the apical, brush-border membrane of epithelial cells in
the distal small intestine [5]. In the ileum, cubam select-
ively mediates absorption of the IF-cobalamin complex
from food, and absorbed cobalamin binds transcobalamin,
a plasma transport protein for delivery of the vitamin to
cells [4].
In addition to the distal small intestine, cubam is
expressed in renal proximal tubular epithelial cells. In
the kidney, cubam mediates reabsorption of a variety of
protein ligands, such as albumin, apo AI (involved in
lipid metabolism), haptoglobin, and vitamin D-binding
protein from the glomerular filtrate [6–9]. Therefore,
cubam dysfunction not only causes intestinal cobalamin
malabsorption but also a mild proteinuria of mid- to
low-molecular weight proteins that are cubam ligands.
The ligand-specific proteinuria is clinically benign but is
a useful diagnostic marker of cubam dysfunction.
The functional cubam complex is composed of cubilin
(CUBN) and amnionless (AMN) subunits [10]. The
recently solved crystal structure [11] of cubam confirms
that three molecules of CUBN form an extracellular
ligand-binding trimer [12]. A single transmembrane AMN
molecule provides apical membrane anchorage of the
trimer and cytoplasmic signaling that initiates clathrin-
mediated endocytosis [13]. In humans [14, 15] and dogs
[16–20] various gene variants in both CUBN and AMN
are found causing hereditary selective intestinal cobalamin
malabsorption with mid- to low-molecular weight pro-
teinuria, an autosomal recessive trait also known as
Imerslund-Gräsbeck syndrome (I-GS) [21, 22]. Though
genetically heterogeneous, the disorder in dogs is
phenotypically quite similar, and the various causative
AMN or CUBN variants are breed-specific. Description
of cobalamin malabsorption in dogs caused by AMN
variants (OMIA 000565–9615) and CUBN variants(OMIA 001786–9615) is curated in the Online Mendel-
ian Inheritance in Animals data base (https://omia.org).
We describe here autosomal recessive selective intestinal
cobalamin malabsorption with proteinuria in Komondor
dogs characterized by failure to thrive, dyshematopoiesis,
and metabolic disturbances during the juvenile period, as
occur in I-GS of other dog breeds and human patients. The
purpose of this study was to determine the molecular defect
underlying I-GS in Komondors and to determine the
disease-allele frequency in Komondor populations of
Hungary and North America.
Results
Clinical signs of I-GS in Komondors
Owners of affected Komondors first noted signs of
failure-to-thrive between 2.5 and 5 months of age that
were progressive until institution of parenteral cobala-
min administration. Typical clinical signs included in-
appetence, vomiting, diarrhea, failure to thrive, and
weakness. One dog exhibited a fine head tremor, and
another had intermittent seizures. On physical exami-
nations the puppies were lethargic and underweight but
of near-normal linear size.
Routine complete blood counts revealed a non-
regenerative, normocytic, normochromic anemia or low-
normal hematocrit. Neutrophil counts were between 900
and 3700/μL (normal range for puppies 5000-12,000/μL)
and some appeared toxic and/or hypersegmented. The
dogs also had a mild thrombocytopenia. Serum chemistry
indicated mildly increased blood urea nitrogen, normal
serum creatinine concentrations, and increased anion
gaps, suggesting a metabolic acidosis. Serum bile acid con-
centrations were normal. Serum cobalamin concentrations
were undetectable (<150 ng/L) or below the lower limited
of normal (250 ng/L). Urinalysis showed mild to moderate
proteinuria by dipstick (2+ to 4+ in concentrated urine).
Urine metabolic screens showed strongly positive methyl-
malonic acid (MMA) spot test results, and quantitative or-
ganic acid analyses revealed extremely high MMA
concentrations of 20,000–37,000mmol/mol creatinine
(normal upper limit = 2mmol/mol creatinine). The mid-
to low-molecular weight proteins found in urine from af-
fected dogs were identified as cubam ligands, including
transferrin, albumin, vitamin D binding-protein, haptoglo-
bin, and apo A1 (Fig. 1).
Detailed clinicopathological information was available
from 5 affected dogs, 3 males and 2 females that presented
over a period of 12 years from both coasts of the United
States and the Midwest (Additional file 1). Family history
of affected Komondors, when available, indicated that par-
ents and other littermates were clinically healthy. The 2
female affected dogs had 3 normal littermates. One of the
affected females died before biochemical or molecular
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Fig. 1 Urine protein analysis of Komondor littermates. Urine samples
containing 200 μg creatinine were desalted and concentrated by
centrifugation through a 10 kDa molecular weight cutoff membrane.
Proteins were separated by 15% SDS-PAGE and visualized by silver
staining. Lane 1 shows urine proteins obtained from an affected dog
(case 5, Additional file 1) after cobalamin replenishment and during
metabolic remission. Lane 2 shows urine proteins from a heterozygous







Fig. 2 Pedigree of a Komondor dog kindred with hereditary selective intes
females, respectively. Filled symbols indicate affected dogs. Offspring in a s
descending from the parents’ symbols. The arrow points to the index case
4 that died without biochemical or molecular diagnosis. Half-filled symbols
CUBN c.NM_001003148.1; c.8746 + 1G > A variant. Genotypes of dogs deter
their symbols. Open symbols indicate dogs which were not genotyped
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the others. The same mating subsequently produced 2
more affected males and 3 normal littermates (Fig. 2). The
2 affected dogs of the second litter were ascertained at 10
weeks of age, before the onset of clinical signs, by measur-
ing serum cobalamin concentrations and urinary MMA
excretion, and life-long parenteral cobalamin treatment
prevented clinical abnormalities. The incidence of the dis-
order in this nuclear family (4 affected, 2 males and 2 fe-
males, of 10 total puppies) was as expected under the
hypothesis of autosomal recessive inheritance (Fisher’s
exact test p < 0.0003).
Cyanocobalamin (400–1000 μg) administered subcuta-
neously or intramuscularly led to rapid clinical responses.
One affected dog was treated with 800 μg of cyanocobala-
min spray administered to oral mucous membranes and
responded well and rapidly. Cyanocobalamin administra-
tion continued with subcutaneous injections every other
week to monthly or with sublingual spray daily, and the
dogs remained clinically asymptomatic. Each affected
puppy rapidly gained weight and became active, and all
other clinical signs resolved, including tremors and sei-
zures. The seizing dog’s phenobarbital and potassium
bromide treatments were discontinued without seizure re-
currence after initiating cobalamin treatment. All labora-
tory abnormalities resolved except for the ligand-specificAG
AGAA GG
AG AGGGAAA
tinal cobalamin malabsorption. Squares and circles are males and
ingle litter are arranged on a horizontal line that connects lines
(case 5, Additional file 1), and the checkered symbol indicates case
indicate carriers of the disease allele determine by genotyping the
mined as in Fig. 3b are indicated below or immediately adjacent to
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Clinical, hematological, and biochemical signs compat-
ible with cobalamin deficiency and mild proteinuria sug-
gested dysfunction of cubam in both ileal brush border
and renal proximal tubular epithelia, but there was also
the possibility of IF dysfunction accompanied by pro-
teinuria of unrelated cause [5, 23]. Cubam dysfunction is
genetically heterogeneous in humans [14, 15], and dogs.
In dogs, the disorder is caused by certain variants of
either CUBN or AMN [16–20] that segregate within cer-
tain breeds. Variants causing IF dysfunction are confined
to the CBLIF locus (previously designated GIF) and thus
far have only been reported in human patients [5, 23].
To simplify interpretation of the many variants expected
in an investigation by whole genome sequencing (WGS)
with comparison to a single reference genome, we
undertook genetic exclusion of the various candidate
genes. We genotyped those members of the nuclear
Komondor family segregating I-GS (Fig. 2) for which
DNA samples were available, including both parents, 3
affected dogs, and 4 clinically normal littermates.
There was a fully informative SNV ~ 6 kb centro-
meric from the 3′ end of AMN and a second inform-
ative SNV ~ 2.1 kb telomeric of the 5′ end of AMN
(Table 1; Additional file 2). Alleles of these AMN-flank-
ing SNVs were in linkage disequilibrium, but none of
the restriction fragment length polymorphisms (RFLPs)
they created segregated with the disease locus (Table 2;
Additional file 2), thus excluding AMN as a candidate
gene. The CBLIF locus was similarly excluded by exam-
ining alleles of an intron 6 pentanucleotide repeat in
the same nuclear family. Neither allele segregated with
the disease locus (Tables 1 and 2; Additional file 2).
Because the CUBN gene is 259 Kb in length, we exam-
ined marker alleles near both ends of the gene (Table 1;
Additional file 2). Alleles of an SSR in CUBN intron 4
and another in intron 56 were in linkage disequilibrium.
Alleles of both SSRs were homozygous in the 3 affected
dogs, heterozygous in both parents and 3 normal litter-
mates, and homozygous wild-type in 1 normal littermate
(Table 2; Additional file 2). These data failed to exclude
CUBN from the disease locus, thus we focused our
search for a disease-causing variant on that candidate
gene.
Whole genome sequencing
Whole genome sequences of 3 I-GS affected, the sire of
1 of them, and a clinically normal Komondor (20–25
coverage each) were compared to the CanFam 3.1 caninereference genome sequence. This revealed 2 homozygous
missense variants in AMN (NM_001002960.1) of the
affected dogs: c.8C >G (p.Ala3Gly) and c.313C > T
(p.Leu105Phe). Both variants were also homozygous in
the clinically normal sire of 1 of the affected dogs, and
both variants were considered tolerant by SIFT [24]. Simi-
larly, there were 4 variants in CBLIF (NM_001005759.1)
that we considered nonpathogenic because, while
homozygous in an affected dog, they were also homozy-
gous in his clinically normal sire: c.41C > T (p.Ala14Val);
c.913G >A (p.Val305Ile); and c.1074-10_1074-2delAATC
TTGCA (does not change the splice acceptor site of
intron 7). A variant c.244A >G (p. Ser82Gly) was hetero-
zygous in both an affected dog and his sire. All the CBLIF
missense variants were considered tolerant by SIFT. There
were no disruptive or missense variants of TCN2, encod-
ing transcobalamin, in any affected dog sequenced.
In CUBN (NM_001003148.1) we observed 2 homozy-
gous SIFT-tolerant variants in the affected dogs that were
also homozygous in the clinically normal sire and, there-
fore, which we did not consider pathogenic: c.6201C >A
in exon 41 (g.19,950,597; p.Phe2018Leu) and c.7175 T > C
in exon 46 (g.19,960,139; p.Val2392Ala). The clinically
normal Komondor’s sequence had an additional homozy-
gous variant c.9362G > C (g.19,999,373; p.Ser3121Thr),
which was tolerant by SIFT analysis.
However, and of particular note, there was a CUBN
variant (NM_001003148.1; c.8746 + 1G > A) at genomic
position chr2:g.19,981,457 (CanFam 3.1), which was
homozygous (A) in the affected dogs, heterozygous (A/
G) in the clinically normal sire, and wildtype sequence
(G/G) in the normal Komondor. This variant obliterates
a splice donor consensus sequence in intron 55, predict-
ing an abnormal RNA splicing pattern, and was thereby
considered pathogenic. We confirmed the variant in all
6 affected Komondors by Sanger sequencing (Fig. 3a).
A search of CUBN variants in the Genome Aggregation
Database [25] (gnomAD; http://gnomad.broadinstitute.
org, accessed Nov. 16, 2018), including WGS of 282,822
healthy humans, revealed 38 variants in the + 1 position of
the 66 intronic splice donor sites (frequency of 2.0 ×
10− 6). None were homozygous.CUBN variant genotyping
We assessed segregation of the putative CUBN disease-
allele in a family and 3 sporadic cases of Komondors with
I-GS using a convenient DNA genotyping assay (Table 1;
Additional file 2) of PCR to produce an amplicon flanking
the variant and restriction enzyme (Bce AI) digestion to
discriminate the alleles (Fig. 3b). The A allele was indi-
cated by failure of the PCR amplicon to be digested except
at the control Bce AI cut site. The 6 affected dogs were
homozygous A, the 3 parental dogs were heterozygous
AB
Fig. 3 a. DNA sequencing electrophoretograms of the CUBN exon 55/intron 55 boundary. Shown are results of a normal control (above) and a
Komondor dog with hereditary selective intestinal cobalamin malabsorption (below). The cartoon indicates the 3′ end of exon 55 (box) and the
5′ end of intron 55 (line) aligned with the sequences. The splice donor consensus has a solid underline in the normal dog sequence. The CUBN
c.NM_001003148.1; c.8746 + 1G > A variant is indicated by the black triangle and a potential cryptic splice donor has a dotted underline in the
affected dog sequence. b. Genotyping of the CUBN c.NM_001003148.1; c.8746 + 1G > A splicing variant in a Komondor family segregating I-GS.
Genomic DNA samples were amplified by PCR using primers flanking the G/A variant of the intron 55 splice donor consensus (Table 1, Additional
file 2). Bce AI digestion fragments of the PCR amplicons were separated on 4% agarose gels. An endonuclease control cut-site created 293 and
68 bp fragments from the 361 bp amplicon. Cutting at the wildtype G recognition site further cut the 293 bp fragment into 237 and 56 bp
fragments. The deduced genotypes are shown below each lane, and symbols above indicate the sex and disease status of each dog as in Fig. 2
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gous G or heterozygous A/G (Table 2; Additional file 2).
We assessed Komondor I-GS allele frequencies in North
America and Hungary using a TaqMan® assay. Of 98 Ko-
mondors genotyped, 12 were heterozygous, and 86 were
homozygous G for the CUBN NM_001003148.1; c.8746 +
1G >A variant. Seven of 42 Komondors from North
America (allele frequency of 8.3%) and 5 of 56 Komondors
from Hungary (allele frequency of 4.5%) were heterozy-
gous (i.e. carriers of the putative disease-allele). Pedigree
analyses revealed distant relatedness among some carriers
in Hungary and to some Komondors in North America,
including 1 of the 3 sporadic cases (Fig. 2). The nearest
common ancestors (top of Fig. 2) to all affected dogs in
the United States whose pedigrees were available were
dogs born in Hungary in 1968 and 1973, respectively, and
subsequently imported into United States breeding pro-
grams. The CUBN c.NM_001003148.1; c.8746 + 1G >A
variant was not observed in 100 dogs of other breeds.Discussion
In contrast to many dog breeds today, the Komondor is
an old breed, brought originally to Hungary in the 12th
and 13th centuries by the Cumans, a Turkish speaking
nomadic tribe [26]. By Hungarian parliamentary decree
in 2004, the Komondor is today recognized as a national
treasure to be protected from genetic admixture. It is a
large breed dog in which adult males average 36–45 kg
and whose traditional vocation was to guard sheep and
goat herds.
The early signs of hereditary selective intestinal cobala-
min deficiency, including poor appetite, muscle wasting
and failure to thrive, can be masked by a long hair coat or
otherwise missed by owners unfamiliar with the rapid
growth of healthy juvenile Komondors. More obvious
signs such as seizures or collapse will bring affected dogs
to veterinary attention, but their condition may be misun-
derstood and considered untreatable, leading to euthanasia.
Failure to recognize and treat the cobalamin deficiency
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progression of the disorder but potentially lethal metabolic
crises complicated by hyperammonemia, ketoacidosis, and/
or hypoglycemia. Megaloblastic dyshematopoiesis, neutro-
penia, and methylmalonic acidemia/−uria are more specific
findings that support the diagnosis of this inborn error of
metabolism. Serum homocysteine is also elevated in
cobalamin-deficient dogs [27, 28], but it is a less specific
finding than elevated MMA and is less reactive to the
deficiency.
In contrast to humans, the anemia of cobalamin defi-
ciency in dogs is not macrocytic when evaluated by
Wintrobe indices [27]. The presence of some large red
blood cells is masked by many misshaped and/or small
RBCs, as indicated by a widened red cell distribution
when evaluated by flow cytometry. Circulating megalo-
blasts may be observed and are too large to be misinter-
preted as nucleated RBCs of other causes, such as lead
poisoning. Neutropenia is a common feature of the co-
balamin deficient dog hemogram, and hypersegmented
neutrophils are usually evident upon careful examination
of blood smears. Dyssynchrony of nuclear and cytoplas-
mic maturation (megaloblastosis) in the erythrocytic and
myelocytic series is evident in bone marrow [27]. As
shown in the affected Komondors here, age of clinical
disease detection and signs varied, but intermittent par-
enteral cobalamin supplementation ameliorated all clin-
ical abnormalities, except the constitutive ligand-specific
proteinuria.
While cobalamin deficiency may have different causes,
severe cobalamin deficiency of several related juvenile
Komondors and complete recovery with parenteral co-
balamin administration indicates a hereditary GI defect in
this breed. Clinical observations in affected dogs showed
that a parenteral megadose (400–1000 μg) of cyanocobala-
min corrected the metabolic disturbances of cobalamin
deficiency in affected Komondors within 2–3 days and
began correction of the hemogram over the ensuing few
weeks. Affected dogs recovered normal weight-for-age
within 2months. Following treatment, however, the initial
supernormal serum cobalamin concentration, which may
be 2–5-fold greater than the high end of the normal refer-
ence range, fell rapidly to below the normal range in
about 2 weeks. This is because serum cobalamin is
bound entirely to transcobalamin in dogs [29] and is
rapidly translocated into cells. In contrast, 70–80% of
serum cobalamin is bound to haptocorrin in humans
[30] and continues to circulate in plasma. The remis-
sion of clinical signs after a single cobalamin megadose
can last for 12 weeks, even in a rapidly growing juven-
ile, despite a gradual rise of methylmalonic acidemia
above normal during that period [31]. In 1 Komondor
studied as an adult, the serum methylmalonic acid con-
centration fell but was not fully suppressed into thenormal range by a single 1000 μg cobalamin treatment,
perhaps due to the large mass of the dog, and despite
the dog remaining clinically normal. Thus, the rationale
for deciding when to treat again cannot be based on
serum cobalamin or serum methylmalonic acid deter-
minations but ought to be rather a pre-determined
interval and dosage that will keep clinical signs of defi-
ciency from reappearing. A typical interval is every 2–4
weeks in I-GS dogs of various breeds.
Also demonstrated here in 1 of the affected Komondors
(case 2), a daily dose of cobalamin (800 μg/day)
administered by sublingual spray can be a successful treat-
ment, but such a regimen does not produce a superior ef-
fect and costs more. The mechanism by which a few
micrograms of an oral cobalamin megadose is absorbed in
the absence of functional IF or cubam is unknown, but the
phenomenon of IF-independent cobalamin absorption
from the proximal small intestine exposed to large doses
was observed in dogs long ago [32, 33]. The non-specific
mechanism of cobalamin absorption is inefficient but
explains how Minot and Murphy’s “liver therapy” could
induce hematologic remission in pernicious anemia pa-
tients in the absence of IF [34]. Their recommended
liver dose (120–240 g/day) contained up to 150 μg of
cobalamin, or 60 times the normal daily requirement of
dietary cobalamin.
We opted for genetic exclusion analyses prior to whole
genome sequencing in this instance because, while the
clinical disorder suggested few candidate genes, sequen-
cing of AMN and CUBN each present difficulty. AMN is
GC rich (65–70%) throughout the gene (GenBank® acces-
sion no. KF445236), so much so that the canine reference
genome has large gaps in the AMN locus and is missing
several exons. The CUBN gene is large, with 67 exons ex-
tending over 259 Kb, and again, the CanFam 3.1 reference
genome is missing exon 32 (compare GenBank® accession
no. AF137068 to reference genome). Of greatest concern
was that without genetic positional information, the inev-
itably numerous sequence variants observed by WGS
would be difficult to interpret. We excluded CBLIF and
AMN as disease loci because alleles of internal or flanking
markers did not segregate in our study kindred with alleles
of an autosomal recessive disease locus.
The all-important assumption of autosomal recessive in-
heritance depends on the definition of the trait under
study, which in this case is juvenile-onset cobalamin defi-
ciency with compatible clinical signs and ligand-specific
proteinuria. This definition does not rule out the possibil-
ity that heterozygous Komondors may have subclinically
reduced cobalamin absorption. However, heterozygotes in
this study were healthy, had serum cobalamin concentra-
tions equally within the normal range as normal control
dogs (data not shown), and had no detectable urinary
cubam ligands (lane 2, Fig. 2). Furthermore, in a study of
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Giant Schnauzers, the heterozygous dog demonstrated co-
balamin absorption equal to unrelated normal control
dogs [27].
While we found several missense variants in CUBN
by WGS, we dismissed them as causative, because they
were tolerated by SIFT and were also homozygous in
clinically healthy Komondor dogs. However, the in-
tronic CUBN c.NM_001003148.1; c.8746 + 1G > A vari-
ant was only homozygous in affected dogs and is likely
pathogenic because it disrupts the splice donor consen-
sus sequence of intron 55. The G nucleotide in that
position is 100% conserved in mammalian introns [35].
Loss of the splice donor predicts exon skipping with
the loss of the 157 bp of exon 55, at a minimum, thus
introducing a shift of the translation reading-frame and
creating a premature stop codon that is 26 codons into
exon 56. The sequence GTGAGC near the 3′ end of
exon 55 (Fig. 3) might be interpreted as a cryptic splice
donor but use of it would delete 7 bp from the mRNA,
again causing a frame-shift and a premature stop codon
at the same place in exon 56. A similar frameshift vari-
ant in I-GS affected Border Collies was demonstrated
to cause ~ 10-fold reduction CUBN mRNA expression
[17], most likely by nonsense-mediated mRNA decay
[36], and failed CUBN protein expression. While ex-
pression studies are optimal for validation of variant
pathogenicity, we had no access to intestinal and/or
renal tissue biopsies to investigate cubam expression in
these privately owned and successfully treated I-GS af-
fected Komondors. Thus, using the American College
of Medical Genetics Standards and Guidelines for inter-
pretation of sequence variants [37], we conclude that
the CUBN c.NM_001003148.1; c.8746 + 1G > A variant
is a highly likely pathogenic null allele. The small
amount of uncertainly that remains due to lack of dir-
ect experimental evidence of an effect on CUBN mRNA
or protein expression will be further reduced as more
Komondor I-GS cases come to light and are genotyped.
In mice, targeted genetic disruptions of either AMN or
CUBN create embryonic lethality [38, 39]. In humans
and dogs, however, many naturally-occurring null alleles
of AMN and CUBN, including early (5′) frameshift vari-
ants and large deletions of the entire CUBN locus, have
been described without evidence of embryonic or fetal
developmental abnormalities [5, 14–20]. Reported mis-
sense or nonsense CUBN variants that cause I-GS in
humans are clustered in the first 28 exons, which encode
regions important for IF-cobalamin binding and AMN-
mediated membrane localization and internalization
(Human Gene Mutation Database, accessed July 27, 2018;
http://www.hgmd.cf.ac.uk/ac/index.php), [5]. In contrast,
the 3 known I-GS-causing CUBN variants of dogs are 2
single-base deletions (c.786delC in Beagles and c.8392delCin Border Collies), and the splice-site variant reported
here, each predicting a frameshift [17–20]. Two of these
are very distal in the gene, well 3′ of exons encoding the
IF-cobalamin-binding site in CUB domains 5–8, and
emphasize the importance of mRNA stability in gene
expression.
The ascertainment of human I-GS patients suggests
that cobalamin malabsorption is the single aspect of
cubam dysfunction that alerts medical clinicians to the
need for treatment intervention and molecular investi-
gation. Urinary loss of the cubam ligands, albumin and
vitamin D-binding protein, may cause phenomena such
as low-grade tubular albuminuria [8, 40] or a subclin-
ical reduction of hydroyxlated forms of vitamin D in
serum. A study in cobalamin treated, affected dogs of
the I-GS Giant Schnauzer line demonstrated signifi-
cantly increased 25-hydroxyvitamin D3 concentrations
in urine, due to failed tubular reabsorption of vitamin
D binding protein, and ~ 55% decreases of serum
25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3
concentrations in serum [6]. Despite these biochemical
abnormalities, we and others have observed no conse-
quences of the proteinuria to the health of adequately
cobalamin-treated I-GS affected dogs, regardless of breed
and, therefore, gene or sequence variant [27, 28, 31, 41–43].
The CUBN c.NM_001003148.1; c.8746 + 1G >A variant
permitted design of simple RFLP and Taqman® assays to
differentiate between homozygous affected, asymptomatic
heterozygous, and wildtype healthy Komondors. While we
did not pursue a randomized survey, screening of Komon-
dors in North America revealed an 8.3% prevalence of the
disease-allele in this small population. Moreover, survey-
ing Komondors in Hungary, the breed’s country of origin,
revealed a disease-allele prevalence of 4.5%. Common
ancestors trace back to dogs born in Hungary in the early
1970s. Thus, the I-GS allele has been segregating in
Komondors for decades and is widespread in the breed
worldwide. The higher allele-frequency in North America
could be due to a founder effect subsequent to import-
ation of a popular sire or dam.
Conclusions
Breed-specific cubam mutations that cause life-threatening
cobalamin deficiency in dogs now include a CUBN
splice-site variant (CUBN c.NM_001003148.1; c.8746 +
1G > A) segregating among Komondors. The disease-
allele appears to be widespread among Komondors in
North America and Hungary. Simple and reliable
allele-specific DNA tests are available so that Komon-
dors with clinical signs suggestive of I-GS may be diag-
nosed early and treated effectively. We also recommend
that Komondors intended for breeding be tested to
identify carriers and prevent production of additional
affected dogs.
Fyfe et al. BMC Veterinary Research          (2018) 14:418 Page 8 of 10Methods
Animals, clinicopathologic and metabolic studies
These investigations included clinical case studies and/
or laboratory analyses of samples from 4 I-GS affected
Komondors, their parents, and 6 healthy littermates in 1
nuclear family plus 3 affected Komondors that occurred
as sporadic cases and 1 of their sires. Owners submitted
samples for DNA isolation and genotyping from 98 add-
itional clinically-normal Komondors in North America
and Hungary to assist with their breeding programs.
Additionally, we studied DNA samples from 100 dogs of
other breeds that were in laboratory archives. Blood and
urine sampling from Komondors were according to
principles and protocols approved by the respective In-
stitutional Animal Use and Care Committees at Mich-
igan State University, University of Pennsylvania, and
University of Tennessee. Owners and local veterinarians
submitted case histories and samples for routine diag-
nostic tests such as blood tests, DNA isolation, meta-
bolic analysis, and urinalysis from dogs of Komondor
kindreds or sporadic cases. Pedigrees were gathered to
determine shared ancestry. Characterization of
cobalamin-deficient dogs included clinical signs, medical
history, routine complete blood counts, serum chemistry
panels, serum cobalamin and folate concentrations,
examination of bone marrow aspirates, and routine and
special urinalyses.
In affected dogs, excess methylmalonic acid excretion
in urine was documented either qualitatively by a spe-
cific reaction with diazotized p-nitroaniline or quantita-
tively by gas chromatography-mass spectroscopy. Urine
proteins were concentrated by centrifugation through a
10 kDa molecular weight cut-off membrane and sepa-
rated by one-dimensional SDS-polyacrylamide gel elec-
trophoresis, and protein identities were confirmed by
antibody reactivity on immunoblots, as previously de-
scribed [6–9, 17, 18].
Molecular genetic investigations
Genetic exclusion analysis
Genomic DNA was prepared from buccal brushes or
EDTA-anticoagulated whole blood by standard methods
[16]. Single nucleotide variants (SNVs) and polymorphic
simple sequence repeat markers (SSRs) in or closely flank-
ing the genes CBLIF, CUBN and AMN were chosen from
a canine reference genome sequence (Broad/CanFam 2.1,
May 2005) as viewed on the University of California Santa
Cruz genome browser [44] with RepeatMasker [45] and
Single Nucleotide Polymorphism database (dbSNP build
131) tracks [46]. However, coordinates given in this report
(Table 1; Additional file 2) are updated to the Broad/
CanFam 3.1 assembly, September 2011. For polymerase
chain reactions (PCR) we used standard primer, deoxy-
nucleotide, and genomic template concentrations, 1.5mM MgCl2, and 2 U Taq polymerase (Invitrogen Corp.,
Carlsbad, CA) in 50 μL reactions. For higher GC tem-
plates 1M betaine was added to the reaction, as noted
in Table 1; Additional file 2. Marker genotyping was by
restriction enzyme digestion and/or Sanger sequencing
of PCR amplicons. Sequences and accompanying elec-
trophoretograms were viewed in the SeqMan program
of the Lasergene sequence analysis suite (DNASTAR®,
Inc., Madison, WI).
Whole genome sequencing (WGS)
DNA samples of 5 Komondor dogs, including 3 affected
dogs of widely separated ancestry, 1 clinically normal sire,
and 1 clinically normal littermate of an affected dog were
prepared for WGS. Genome libraries were prepared using
Illumina® TruSeq Nano LT Kit (FC-121-4001 & FC-121-
4002; Illumina®, San Diego, CA). Briefly, genomic DNA
was fragmented, end-repaired and adenylated before
ligation with the corresponding unique index adapters
and amplified for WGS. All samples were sequenced on
the Illumina HiSeq 2500 platform by paired-end se-
quencing. Average genome sequence coverage for each
dog was 20-25X (The datasets generated and analyzed
during the current study are available in the BioProject
ID: PRJNA486818 repository, http://www.ncbi.nlm.nih.-
gov/bioproject/486818 and BioSample accessions: SAM
N09865705, SAMN09865706, SAMN09865707, SAMN
09865708, SAMN09865709; Release date: 2019-01-01.
Genomic data were searched for variants using the
CanFam 3.1 reference sequence with a focus on the po-
tential candidate genes CUBN, AMN, CBLIF, and TCN2.
Disruptive variants, homozygous in the affected dogs
and heterozygous in the parental dog were prioritized as
potential disease-causing candidates. Functional effects
of missense variants were examined by Sorting Intoler-
ant From Tolerant (SIFT) analysis [24] and resequencing
DNA of clinically affected and normal dogs.
CUBN variant genotyping
The sequence variant CUBN c.NM_001003148.1; c.8746
+ 1G >A (chr2:g.19,981,457 CanFam 3.1) was genotyped
in all members of the I-GS Komondor kindred and spor-
adic cases using PCR amplification primers as listed in
Table 1; Additional file 2, followed by Bce AI restriction
digestion of the amplicon (New England BioLabs®, Inc.,
Ipswich, MA). Digested amplification products were sepa-
rated on 4% agarose gels. An allelic discrimination real
time PCR assay was designed for population-wide geno-
typing of the NM_001003148.1; c.8746 + 1G >A variant
(Forward Primer: CAGGGCTTCTCTGCATCCT; Re-
verse Primer: GACCTCCCGGGTTGGTTTT; Probe 1
(VIC Dye): TTGTGAGCCGTAAGTAG; Probe 2 (FAM
Dye): TTGTGAGCCATAAGTAG). Primers and probes
were obtained as a Custom Taqman® SNP Genotyping
Fyfe et al. BMC Veterinary Research          (2018) 14:418 Page 9 of 10Assay (Applied Biosystems, Life Technologies, Grand
Island, NY). A total of 98 Komondors from North
America and Hungary and archived samples from 100
other dogs of different breeds were screened using the
TaqMan® assay following standard conditions.Additional files
Additional file 1 Format is Adobe Portable Document Format (.pdf),
titled Detailed clinical descriptions and course of disease before and
following specific treatment. The file summarizes 4 clinical cases of I-GS
in young Komondors as they were presented to veterinary clinicians
across the USA. (DOCX 22 kb)
Additional file 2 Format is Adobe Portable Document Format (.pdf),
titled Genetic exclusion markers. The file contains 2 tables: Table 1
describes genetic exclusion markers used to query biological candidate
genes for segregation of alleles with the disease locus, and Table 2
shows alleles of the markers described in Table 1 in each member of a
family of Komondors segregating I-GS. (DOCX 33 kb)
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